Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

uniQure is well-poised for success due to its diverse pipeline, strong intellectual property protection, and impressive clinical results for its lead gene therapy candidates. The company's recent data on AMT-191 for Fabry disease demonstrates durable, dose-dependent enzymatic production, positioning it as a potential one-time treatment for this rare genetic disorder. Additionally, the company's partnership with Bristol Myers Squibb for cardiovascular diseases further strengthens its platform and potential for future growth. With a focus on addressing unmet medical needs and a strong balance sheet, uniQure is positioned for long-term success and remains a top pick for investors in the gene therapy space.

Bears say

uniQure is a gene therapy company that has a limited pipeline with its lead candidate, AMT-130, facing potential delays with the FDA requiring a traditional sham-controlled trial for Huntington's disease. In addition, the company heavily relies on the success of AMT-130, and any setbacks or failures could adversely affect their business. Financial risks are also apparent, as the company has no revenue-generating products and is dependent on external funding for its development and commercialization efforts. The recent departure of the FDA's CBER director, known for supporting flexibility in approvals for rare diseases, adds further uncertainty for uniQure's future.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.